Anebulo Pharmaceuticals Inc. Announces Voluntary Delisting from Nasdaq and Deregistration with the SEC
Anebulo Pharmaceuticals Inc. (NASDAQ: ANEB), a clinical‑stage biopharmaceutical company headquartered in Lakeway, United States, confirmed that it will voluntarily delist its common stock from the Nasdaq stock exchange and deregister its securities with the U.S. Securities and Exchange Commission (SEC). The announcement was made by the company’s board of directors on Thursday, February 6, 2026.
Rationale for Delisting
The board cited a strategic shift toward concentrating on its core clinical development programs and a desire to reduce the regulatory and compliance costs associated with maintaining a public listing. By deregistering with the SEC and delisting from Nasdaq, Anebulo intends to streamline its operations and focus resources on advancing its product pipeline, which includes therapies for acute cannabis‑induced toxic effects and broader addiction disorders.
Market Reaction
Shares of Anebulo traded on Nasdaq at a close of $0.8212 on Thursday, down 13.6 % from the previous day’s close of $0.9501. The stock experienced a low of $0.8031 during the session. Approximately 42,620 shares were traded, a 31 % decline from the average daily volume of 62,014 shares. At the time of reporting, the company’s market capitalization stood at $33.73 million, and its price‑earnings ratio was -3.57.
Financial Performance
Anebulo reported quarterly earnings of ($0.05) per share for the quarter that ended on November 13, 2025, surpassing analysts’ consensus estimates of ($0.12) by $0.07. For the current fiscal year, analysts project earnings of -0.52 per share.
The company’s share price has fluctuated within a 52‑week range of $0.8 to $3.42, with a 200‑day simple moving average of $2.14 and a 50‑day simple moving average of $1.46. The beta is reported at -0.81, indicating a negative correlation with broader market movements.
Investor Activity
Institutional investors currently own 28.40 % of Anebulo’s outstanding shares. Notably, Goldman Sachs Group Inc. disclosed a new position of 47,954 shares, valued at approximately $62,000, in its most recent Form 13F filing. This position represents roughly 0.12 % of the company’s total shares.
Company Focus
Anebulo remains dedicated to developing intranasal therapies for the acute treatment of migraine and for substance use disorders, including cannabinoid overdose. Its lead product candidate, ANEB‑001, is an intranasal formulation of dihydroergotamine mesylate intended to deliver rapid relief from migraine attacks while minimizing gastrointestinal side effects common to oral treatments. The company is advancing ANEB‑001 through pivotal trials in the United States and plans to submit a new drug application.
Conclusion
Anebulo Pharmaceuticals’ decision to delist from Nasdaq and deregister with the SEC marks a significant shift in its corporate strategy. The move is expected to reduce regulatory burdens and allow the company to focus more directly on its clinical development programs, particularly in the areas of acute cannabis toxicity and broader addiction therapeutics.
